Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Cardiotoxicity 4Prostatic Neoplasms 3Lung Neoplasms 3Hematologic Neoplasms 3Heart Failure 3Small Cell Lung Carcinoma 2Multiple Myeloma 2Leukemia 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Ventricular Dysfunction, Left 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Sleep Initiation and Maintenance Disorders 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1

Interventions

Paclitaxel 4Carboplatin 4Pemetrexed 2Palliative Care 2Gemcitabine 2temsirolimus 1rucaparib 1pembrolizumab 1niraparib 1nintedanib 1nilotinib 1liposomal doxorubicin 1fosaprepitant 1atezolizumab 1argatroban 1Topotecan 1Thrombopoietin 1Palonosetron 1Ocoxin 1Laparoscopy 1Heparin, Low-Molecular-Weight 1Filgrastim 1Electrocardiography 1Educational Status 1Dexamethasone 1Darbepoetin alfa 1Cognitive Behavioral Therapy 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Genital Neoplasms, Female × Electrocardiography × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡